Search for: "Little v. Janssen Research "
Results 1 - 18
of 18
Sorted by Relevance
|
Sort by Date
27 Sep 2009, 2:30 pm
In Re '318 Patent Infringment Litigation: Janssen Pharmaceutica v. [read post]
23 Oct 2009, 4:12 pm
In In re ‘318 Patent Infringement Litigation (Janssen Pharmaceutica N.V. v. [read post]
12 Aug 2014, 8:00 pm
Janssen Biotech, Inc., No. 2013-1338, 1346 (Fed. [read post]
28 Apr 2019, 7:45 am
In Janssen v Teva (2009) the Federal Circuit stated that mere plausibility does not suffice to meet this requirement, if it did then patents could be obtained for little more than “respectable guesses”. [read post]
6 Aug 2009, 6:50 am
Janssen Pharmaceutica, Inc., 288 Fed. [read post]
14 Aug 2009, 1:04 am
Janssen Pharmaceutica, Inc., 288 Fed. [read post]
14 Aug 2009, 1:04 am
Janssen Pharmaceutica, Inc., 288 Fed. [read post]
14 Aug 2009, 1:04 am
Janssen Pharmaceutica, Inc., 288 Fed. [read post]
23 Apr 2024, 10:28 am
Sanofi, 598 U.S. 594 (2023) (the roadmap amounts to little more than a research assignment). [read post]
25 Jan 2017, 10:48 pm
Birss J agreed with Floyd J in Actavis v Janssen [2008] EWHC 1422 (Pat) that the presence of another fairly remote possibility did not preclude a finding of “inevitable result”. [read post]
13 May 2010, 12:27 pm
Janssen Pharmaceutica, Inc., 288 Fed. [read post]
27 Dec 2011, 9:56 am
Janssen Pharmaceuticals, Inc., 951 N.E.2d 1238 (Ill. [read post]
12 Apr 2007, 1:33 am
See State v. [read post]
30 Jan 2022, 4:46 pm
On 28 January 2022 Warby LJ refused permission to appeal in Wright v McCormack. [read post]
29 Aug 2016, 1:19 pm
Risperdal is the name Janssen patented and used when marketing the product. [read post]
1 Oct 2009, 2:14 am
We discussed Fields v. [read post]
11 Dec 2018, 11:18 am
The suggestion that Blacklock’s business cannot survive in the face of the minor and discrete use that took place here is essentially an admission that the market places little value on Blacklock’s work-product. [read post]
28 Apr 2011, 3:18 pm
[T]he determination under comment k that the design of a product is unavoidably unsafe and yet affords benefits outweighing its risks varies little from the determination under negligence law that the designing and marketing of the product was reasonably done. . . . [read post]
